Insitro, AstraZeneca strike AI drug-discovery deal worth up to $1.46 billion

Insitro and AstraZeneca have agreed to work together on AI-assisted drug discovery for metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies, two conditions the companies describe as biologically heterogeneous and difficult to treat. The deal gives insitro $40 million upfront, with the company eligible for up to approximately $1.46 billion in discovery, development and commercial milestones, plus single-digit royalties on potential global sales.

Under the worldwide exclusive research collaboration, insitro will use its Virtual Human platform to investigate causal disease biology and advance targets nominated by AstraZeneca through to development candidate. AstraZeneca will take responsibility for clinical development, regulatory work and commercialization. The announcement does not specify a timeline for identifying targets or advancing candidates.

The partnership applies insitro’s machine-learning approach to diseases where patients grouped under the same diagnosis may have different underlying biology, the company said. Insitro describes Virtual Human as a platform built on human and cellular data to identify disease drivers; the announcement offers no results from this collaboration, which is a discovery agreement rather than evidence that a treatment has been found or tested in patients.

The deal adds to insitro’s existing pharmaceutical collaborations, which the company lists as including Bristol Myers Squibb, Eli Lilly and Gilead. Insitro also says it has nine programs in its pipeline, including liver-fat and fibrosis regulators it expects to enter clinical development in early 2027; those statements are company-provided context, not milestones under the AstraZeneca agreement.